SK10392001A3 - Farmaceutické prostriedky na liečbu alebo prevenciu psychiatrických ochorení alebo porúch centrálneho nervového systému obsahujúce EPA - Google Patents

Farmaceutické prostriedky na liečbu alebo prevenciu psychiatrických ochorení alebo porúch centrálneho nervového systému obsahujúce EPA Download PDF

Info

Publication number: SK10392001A3
Authority: SK; Slovakia
Prior art keywords: epa; disease; disorder; medicament; treatment
Prior art date: 1999-01-27

Application number

SK1039-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Malcolm Peet

Krishnarao Sitamrao Vaddadi

Original Assignee

Laxdale Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2000-01-21

Publication date

2002-02-05

2000-01-21 Application filed by Laxdale Limited filed Critical Laxdale Limited

2002-02-05 Publication of SK10392001A3 publication Critical patent/SK10392001A3/sk

Links

208000020016 psychiatric disease Diseases 0.000 title claims description 40
208000012902 Nervous system disease Diseases 0.000 title claims description 18
208000025966 Neurological disease Diseases 0.000 title claims description 17
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 82
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 78
229940079593 drug Drugs 0.000 claims abstract description 57
238000011282 treatment Methods 0.000 claims abstract description 55
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 39
229930195729 fatty acid Natural products 0.000 claims abstract description 39
239000000194 fatty acid Substances 0.000 claims abstract description 39
150000004665 fatty acids Chemical class 0.000 claims abstract description 38
201000000980 schizophrenia Diseases 0.000 claims abstract description 35
208000019901 Anxiety disease Diseases 0.000 claims abstract description 15
208000018737 Parkinson disease Diseases 0.000 claims abstract description 15
230000036506 anxiety Effects 0.000 claims abstract description 15
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 12
208000013403 hyperactivity Diseases 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
208000019116 sleep disease Diseases 0.000 claims abstract description 7
208000020685 sleep-wake disease Diseases 0.000 claims abstract 4
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 140
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 137
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 126
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 126
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 55
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 55
201000010099 disease Diseases 0.000 claims description 53
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 50
230000000694 effects Effects 0.000 claims description 44
239000000203 mixture Substances 0.000 claims description 33
235000020669 docosahexaenoic acid Nutrition 0.000 claims description 30
206010012289 Dementia Diseases 0.000 claims description 28
239000008194 pharmaceutical composition Substances 0.000 claims description 27
229940090949 docosahexaenoic acid Drugs 0.000 claims description 25
208000020925 Bipolar disease Diseases 0.000 claims description 23
208000035475 disorder Diseases 0.000 claims description 23
229960004170 clozapine Drugs 0.000 claims description 19
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical group C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 19
238000000034 method Methods 0.000 claims description 19
208000023105 Huntington disease Diseases 0.000 claims description 18
208000019906 panic disease Diseases 0.000 claims description 18
206010033664 Panic attack Diseases 0.000 claims description 17
239000002858 neurotransmitter agent Substances 0.000 claims description 16
150000003904 phospholipids Chemical group 0.000 claims description 16
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 14
229960005017 olanzapine Drugs 0.000 claims description 12
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 12
-1 risperdone Chemical compound 0.000 claims description 12
208000028683 bipolar I disease Diseases 0.000 claims description 11
208000015122 neurodegenerative disease Diseases 0.000 claims description 11
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 10
230000004060 metabolic process Effects 0.000 claims description 10
230000004770 neurodegeneration Effects 0.000 claims description 10
206010015037 epilepsy Diseases 0.000 claims description 9
201000006417 multiple sclerosis Diseases 0.000 claims description 9
208000006011 Stroke Diseases 0.000 claims description 8
229960003878 haloperidol Drugs 0.000 claims description 7
230000000926 neurological effect Effects 0.000 claims description 7
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 6
208000020401 Depressive disease Diseases 0.000 claims description 6
208000028017 Psychotic disease Diseases 0.000 claims description 6
206010041250 Social phobia Diseases 0.000 claims description 6
YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 5
239000003693 atypical antipsychotic agent Substances 0.000 claims description 5
230000006399 behavior Effects 0.000 claims description 5
230000004071 biological effect Effects 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
229960001076 chlorpromazine Drugs 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 5
208000027866 inflammatory disease Diseases 0.000 claims description 5
229960004488 linolenic acid Drugs 0.000 claims description 5
229960000652 sertindole Drugs 0.000 claims description 5
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 5
229960000607 ziprasidone Drugs 0.000 claims description 5
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 5
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 4
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 4
206010019196 Head injury Diseases 0.000 claims description 4
201000004810 Vascular dementia Diseases 0.000 claims description 4
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 4
210000005095 gastrointestinal system Anatomy 0.000 claims description 4
210000001503 joint Anatomy 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
210000004558 lewy body Anatomy 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
230000003647 oxidation Effects 0.000 claims description 4
238000007254 oxidation reaction Methods 0.000 claims description 4
208000022821 personality disease Diseases 0.000 claims description 4
230000000306 recurrent effect Effects 0.000 claims description 4
210000004994 reproductive system Anatomy 0.000 claims description 4
210000002345 respiratory system Anatomy 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
208000022610 schizoaffective disease Diseases 0.000 claims description 4
230000008054 signal transmission Effects 0.000 claims description 4
206010003591 Ataxia Diseases 0.000 claims description 3
208000001914 Fragile X syndrome Diseases 0.000 claims description 3
206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
208000024777 Prion disease Diseases 0.000 claims description 3
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
230000005754 cellular signaling Effects 0.000 claims description 3
238000011260 co-administration Methods 0.000 claims description 3
235000004626 essential fatty acids Nutrition 0.000 claims description 3
208000023516 stroke disease Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
238000003786 synthesis reaction Methods 0.000 claims description 3
206010000117 Abnormal behaviour Diseases 0.000 claims description 2
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 2
208000014674 injury Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 10
210000003169 central nervous system Anatomy 0.000 claims 4
210000003491 skin Anatomy 0.000 claims 3
206010061216 Infarction Diseases 0.000 claims 2
230000007574 infarction Effects 0.000 claims 2
239000003176 neuroleptic agent Substances 0.000 claims 2
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 1
206010019233 Headaches Diseases 0.000 claims 1
239000013256 coordination polymer Substances 0.000 claims 1
IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 1
231100000869 headache Toxicity 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
230000006735 deficit Effects 0.000 abstract description 5
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 36
235000021342 arachidonic acid Nutrition 0.000 description 18
229940114079 arachidonic acid Drugs 0.000 description 18
208000024891 symptom Diseases 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
230000006378 damage Effects 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
230000006872 improvement Effects 0.000 description 14
239000012528 membrane Substances 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
102100037611 Lysophospholipase Human genes 0.000 description 13
108010058864 Phospholipases A2 Proteins 0.000 description 13
238000009472 formulation Methods 0.000 description 13
210000002569 neuron Anatomy 0.000 description 13
102000015439 Phospholipases Human genes 0.000 description 12
108010064785 Phospholipases Proteins 0.000 description 12
230000005856 abnormality Effects 0.000 description 11
238000001994 activation Methods 0.000 description 11
239000000935 antidepressant agent Substances 0.000 description 11
239000000902 placebo Substances 0.000 description 11
229940068196 placebo Drugs 0.000 description 11
229940005513 antidepressants Drugs 0.000 description 10
210000004556 brain Anatomy 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
206010033557 Palpitations Diseases 0.000 description 9
230000004913 activation Effects 0.000 description 9
239000002775 capsule Substances 0.000 description 9
239000005516 coenzyme A Substances 0.000 description 8
229940093530 coenzyme a Drugs 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
235000021323 fish oil Nutrition 0.000 description 8
230000033001 locomotion Effects 0.000 description 8
230000019491 signal transduction Effects 0.000 description 8
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical group CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 7
206010039424 Salivary hypersecretion Diseases 0.000 description 7
230000000994 depressogenic effect Effects 0.000 description 7
229910052744 lithium Inorganic materials 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 6
208000004547 Hallucinations Diseases 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
206010022998 Irritability Diseases 0.000 description 6
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
206010026749 Mania Diseases 0.000 description 6
208000008630 Sialorrhea Diseases 0.000 description 6
208000015114 central nervous system disease Diseases 0.000 description 6
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 6
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000009471 action Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
235000021122 unsaturated fatty acids Nutrition 0.000 description 5
150000004670 unsaturated fatty acids Chemical class 0.000 description 5
206010013954 Dysphoria Diseases 0.000 description 4
206010028347 Muscle twitching Diseases 0.000 description 4
206010033864 Paranoia Diseases 0.000 description 4
208000027099 Paranoid disease Diseases 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000002876 beta blocker Substances 0.000 description 4
229940097320 beta blocking agent Drugs 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000002354 daily effect Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000000698 schizophrenic effect Effects 0.000 description 4
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000011301 standard therapy Methods 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
108700016155 Acyl transferases Proteins 0.000 description 3
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 3
102000004108 Neurotransmitter Receptors Human genes 0.000 description 3
108090000590 Neurotransmitter Receptors Proteins 0.000 description 3
206010043118 Tardive Dyskinesia Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
102000045404 acyltransferase activity proteins Human genes 0.000 description 3
108700014220 acyltransferase activity proteins Proteins 0.000 description 3
239000000164 antipsychotic agent Substances 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
230000000949 anxiolytic effect Effects 0.000 description 3
229940005530 anxiolytics Drugs 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000036461 convulsion Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000002635 electroconvulsive therapy Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002595 magnetic resonance imaging Methods 0.000 description 3
229960001344 methylphenidate Drugs 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
239000002547 new drug Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
229960004431 quetiapine Drugs 0.000 description 3
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
230000035939 shock Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229960004496 zotepine Drugs 0.000 description 3
HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 3
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
206010054196 Affect lability Diseases 0.000 description 2
208000000044 Amnesia Diseases 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
108010009685 Cholinergic Receptors Proteins 0.000 description 2
206010008748 Chorea Diseases 0.000 description 2
101150049660 DRD2 gene Proteins 0.000 description 2
201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
208000012661 Dyskinesia Diseases 0.000 description 2
102000018899 Glutamate Receptors Human genes 0.000 description 2
108010027915 Glutamate Receptors Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
208000009829 Lewy Body Disease Diseases 0.000 description 2
201000002832 Lewy body dementia Diseases 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
208000026139 Memory disease Diseases 0.000 description 2
206010027951 Mood swings Diseases 0.000 description 2
208000016285 Movement disease Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
NCYSTSFUYSFMEO-OBLTVXDOSA-N PGI3 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C\C=C/CC)[C@H](O)C[C@@H]21 NCYSTSFUYSFMEO-OBLTVXDOSA-N 0.000 description 2
208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
102000034337 acetylcholine receptors Human genes 0.000 description 2
108010069175 acyl-CoA transferase Proteins 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
230000036528 appetite Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
208000025307 bipolar depression Diseases 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000012601 choreatic disease Diseases 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229960001653 citalopram Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000003001 depressive effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
229940049906 glutamate Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000003140 lateral ventricle Anatomy 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
230000006984 memory degeneration Effects 0.000 description 2
208000023060 memory loss Diseases 0.000 description 2
230000036651 mood Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
235000020660 omega-3 fatty acid Nutrition 0.000 description 2
229940012843 omega-3 fatty acid Drugs 0.000 description 2
239000006014 omega-3 oil Substances 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000004044 response Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960004940 sulpiride Drugs 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960002784 thioridazine Drugs 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
208000035657 Abasia Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000024985 Alport syndrome Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000007415 Anhedonia Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
102000014461 Ataxins Human genes 0.000 description 1
108010078286 Ataxins Proteins 0.000 description 1
102000004321 Atrophin-1 Human genes 0.000 description 1
108090000806 Atrophin-1 Proteins 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 1
101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
206010008025 Cerebellar ataxia Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000005870 Coenzyme A Ligases Human genes 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
206010014489 Elliptocytosis Diseases 0.000 description 1
206010014935 Enzyme abnormality Diseases 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019070 Hallucination, auditory Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000780208 Homo sapiens Long-chain-fatty-acid-CoA ligase 4 Proteins 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010062018 Inborn error of metabolism Diseases 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
101710082559 Long chain acyl-CoA synthetase 4 Proteins 0.000 description 1
108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
102100034319 Long-chain-fatty-acid-CoA ligase 4 Human genes 0.000 description 1
101710159337 Long-chain-fatty-acid-CoA ligase 4 Proteins 0.000 description 1
208000002569 Machado-Joseph Disease Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000036626 alertness Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
229940124604 anti-psychotic medication Drugs 0.000 description 1
230000002932 anti-schizophrenic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
208000018300 basal ganglia disease Diseases 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
230000005821 brain abnormality Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
208000025434 cerebellar degeneration Diseases 0.000 description 1
201000004559 cerebral degeneration Diseases 0.000 description 1
229940127243 cholinergic drug Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960000632 dexamfetamine Drugs 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
235000007882 dietary composition Nutrition 0.000 description 1
XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
230000004139 eicosanoid metabolism Effects 0.000 description 1
230000006397 emotional response Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229960002419 flupentixol Drugs 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000003215 hereditary nephritis Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000016245 inborn errors of metabolism Diseases 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960000423 loxapine Drugs 0.000 description 1
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000006386 memory function Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
229940042053 methotrimeprazine Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000000199 molecular distillation Methods 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000020763 muscle atrophy Effects 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
230000037360 nucleotide metabolism Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000000803 paradoxical effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
229960000769 periciazine Drugs 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
229960003634 pimozide Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
210000002637 putamen Anatomy 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
208000026451 salivation Diseases 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical class [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000007039 two-step reaction Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1039-2001A 1999-01-27 2000-01-21 Farmaceutické prostriedky na liečbu alebo prevenciu psychiatrických ochorení alebo porúch centrálneho nervového systému obsahujúce EPA SK10392001A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9901809.5A GB9901809D0 (en)	1999-01-27	1999-01-27	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
PCT/GB2000/000164 WO2000044361A2 (en)	1999-01-27	2000-01-21	Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders

Publications (1)

Publication Number	Publication Date
SK10392001A3 true SK10392001A3 (sk)	2002-02-05

Family

ID=10846603

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1039-2001A SK10392001A3 (sk)	1999-01-27	2000-01-21	Farmaceutické prostriedky na liečbu alebo prevenciu psychiatrických ochorení alebo porúch centrálneho nervového systému obsahujúce EPA

Country Status (34)

Country	Link
US (10)	US6384077B1 (sh)
EP (2)	EP1148873B1 (sh)
JP (1)	JP4959055B2 (sh)
KR (1)	KR100760038B1 (sh)
CN (2)	CN1739496A (sh)
AT (1)	ATE300296T1 (sh)
AU (1)	AU3065700A (sh)
BR (1)	BR0007743A (sh)
CA (1)	CA2360776C (sh)
CZ (1)	CZ20012695A3 (sh)
DE (1)	DE60021525T2 (sh)
DK (1)	DK1148873T3 (sh)
EE (1)	EE04629B1 (sh)
ES (1)	ES2246825T3 (sh)
GB (1)	GB9901809D0 (sh)
HK (1)	HK1039564B (sh)
HR (1)	HRP20010558A2 (sh)
HU (1)	HU226713B1 (sh)
IL (2)	IL144502A0 (sh)
IS (1)	IS5988A (sh)
MX (1)	MXPA01007662A (sh)
MY (1)	MY136927A (sh)
NO (1)	NO20013546L (sh)
NZ (1)	NZ513172A (sh)
PL (1)	PL199778B1 (sh)
PT (1)	PT1148873E (sh)
RS (1)	RS50133B (sh)
RU (1)	RU2260423C2 (sh)
SK (1)	SK10392001A3 (sh)
TR (2)	TR200504156T2 (sh)
TW (1)	TWI228041B (sh)
UA (1)	UA76405C2 (sh)
WO (1)	WO2000044361A2 (sh)
ZA (1)	ZA200106105B (sh)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2000074784A1 (en) *	1999-06-09	2000-12-14	Eli Lilly And Company	Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
US6737078B1 (en) *	1999-11-24	2004-05-18	The Iams Company	Process for enhancing canine and feline reproductive performance
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
US20050032897A1 (en) *	2000-11-22	2005-02-10	The Iams Company	Process for enhancing canine and feline reproductive performance
NL1019368C2 (nl) *	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en)	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
GB0210212D0 (en) *	2002-05-03	2002-06-12	Univ Southampton	Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
NZ548508A (en) *	2002-05-03	2008-04-30	Pronova Biocare As	Use of EPA and DHA in preventing cerebral damage wherein the dosage ranges from 0.5 to 5.0g of EPA and/or DHA daily
EP2295529B2 (en) *	2002-07-11	2022-05-18	Basf As	Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) *	2002-07-11	2002-07-11	Pronova Biocare As	A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
US7410663B2 (en) *	2002-08-07	2008-08-12	Kao Corporation	Oil or fat composition
GB0221480D0 (en) *	2002-09-16	2002-10-23	Laxdale Ltd	Treatment of anorexia nervosa (AN) and bulimia
GB0228079D0 (en) *	2002-12-02	2003-01-08	Laxdale Ltd	Huntington's Disease
GB0301701D0 (en) *	2003-01-24	2003-02-26	Ensay Ltd	Psoriasis and Eicosapentaenoic acid
GB0311081D0 (en) *	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
JP2007502805A (ja) *	2003-08-18	2007-02-15	ビーティージー・インターナショナル・リミテッド	神経変性状態の処置
US20050074443A1 (en) *	2003-10-03	2005-04-07	Treadwell Benjamin V.	Methods of attenuating autoimmune disease and compositions useful therefor
FR2860976B1 (fr) *	2003-10-20	2006-02-10	Ravi Shrivastava	Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
EP1683519A4 (en) *	2003-11-14	2009-04-01	Mochida Pharm Co Ltd	PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
US6936598B2 (en) *	2003-11-21	2005-08-30	Hill's Pet Nutrition, Inc.	Composition and method
US7754677B2 (en) *	2003-12-05	2010-07-13	Hill's Pet Nutrition, Inc.	Composition and method for reducing diarrhea in a mammal
GB2409644B (en) *	2003-12-31	2005-12-21	Igennus Ltd	Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
ITMI20040069A1 (it) *	2004-01-21	2004-04-21	Tiberio Bruzzese	Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
UA91512C2 (ru)	2004-07-19	2010-08-10	Биокон Лимитед	Коньюгати олигомеров инсулина, их композиция (варианты) и применение
DK1796658T3 (en) *	2004-09-21	2016-06-27	Btg Int Ltd	dopaminergic mimetics
US20100021555A1 (en) *	2004-10-15	2010-01-28	Karl Geiringer	Compositions containing high omega-3 and low saturated fatty acid levels
GB0425932D0 (en) *	2004-11-25	2004-12-29	Btg Int Ltd	Structured phospholipids
GB2421909A (en) *	2004-12-23	2006-07-12	Laxdale Ltd	Pharmaceutical compositions comprising EPA and methods of use
US8324276B2 (en)	2005-01-24	2012-12-04	Pronova Biopharma Norge As	Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006077495A1 (en) *	2005-01-24	2006-07-27	Pronova Biocare As	Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
GB0504333D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Treatment of cytokine dysregulation
GB0504362D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
CN101213281B (zh) *	2005-05-04	2013-03-13	普罗诺瓦生物医药挪威公司	新的dha衍生物及其作为药物的用途
JP5337479B2 (ja) *	2005-05-04	2013-11-06	プロノヴァ・バイオファーマ・ノルゲ・アーエス	新規化合物
US8367725B2 (en)	2005-07-08	2013-02-05	Mochida Pharmaceutical Co., Ltd.	Composition and/or method for preventing onset and/or recurrence of cardiovascular events
KR20180026556A (ko) *	2005-07-08	2018-03-12	디에스엠 아이피 어셋츠 비.브이.	치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
ITMI20051560A1 (it) *	2005-08-10	2007-02-11	Tiberio Bruzzese	Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
ES2277557B1 (es)	2005-12-21	2008-07-01	Proyecto Empresarial Brudy, S.L.	Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
MX2008008171A (es)	2005-12-21	2008-11-12	Brudy Technology S L	Uso de dha epa o epa derivado de dha para tratamiento de una patologia asociada al daño celular oxidante.
PL2046312T3 (pl) *	2006-07-14	2021-02-08	Kaydence Pharma As	Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
BRPI0717972A2 (pt) *	2006-11-01	2013-11-12	Pronova Biopharma Norge As	Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
CN101535238A (zh) *	2006-11-01	2009-09-16	普罗诺瓦生物医药挪威公司	作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
JP5552314B2 (ja) *	2006-11-01	2014-07-16	プロノヴァバイオファーマノルゲアーエス	新規脂質化合物
RU2509071C2 (ru) *	2006-11-01	2014-03-10	Пронова Биофарма Норге Ас	Новые липидные соединения
WO2008128166A1 (en) *	2007-04-13	2008-10-23	Concert Pharmaceuticals Inc.	Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090088400A1 (en)	2007-09-11	2009-04-02	Puymirat Jack	Prostaglandin e2 modulation and uses thereof
US9241908B2 (en)	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
KR20100100818A (ko) *	2007-10-31	2010-09-15	프로노바 바이오파마 노르지 에이에스	새로운 ｄｈａ 유도체 및 약물로서 그들의 사용
US20090182049A1 (en) *	2008-01-16	2009-07-16	Joar Arild Opheim	Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
WO2010028067A1 (en)	2008-09-02	2010-03-11	Amarin Corporation Plc	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010027266A1 (en) *	2008-09-05	2010-03-11	Van De Langenberg, Hendrikus Theodorus Ardina Hubertus	Means and methods for counteracting neurological disorders
WO2010028419A1 (en)	2008-09-09	2010-03-18	Orygen Research Centre	Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) *	2008-09-09	2017-03-16	Orygen Research Centre	Prevention of psychotic disorders and/or treatment of psychotic symptoms
EP3865128A1 (en)	2009-02-10	2021-08-18	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
CA2754860C (en) *	2009-03-09	2020-02-25	Pronova Biopharma Norge As	Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
GB0904300D0 (en)	2009-03-12	2009-04-22	Amarin Neuroscience Ltd	Essential fatty acid compounds
AU2014203034B2 (en) *	2009-04-29	2016-09-15	Amarin Pharmaceuticals Ireland Limited	Stable pharmaceutical composition and methods of using same
CN104856985B (zh)	2009-04-29	2019-01-04	阿马里纳制药爱尔兰有限公司	稳定的药物组合物和使用其的方法
CN104042617A (zh)	2009-04-29	2014-09-17	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
KR20120016677A (ko) *	2009-06-15	2012-02-24	아마린 파마, 인크.	병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
KR101798670B1 (ko)	2009-09-23	2017-11-16	아마린 코포레이션 피엘씨	오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
JP2011136948A (ja) *	2009-12-28	2011-07-14	Nisshin Oillio Group Ltd	うつ病又はうつ状態の予防又は治療用油脂組成物
US20110178105A1 (en) *	2010-01-15	2011-07-21	E.I. Du Pont De Nemours And Company	Clinical benefits of eicosapentaenoic acid in humans
ES2750365T3 (es) *	2010-03-04	2020-03-25	Amarin Pharmaceuticals Ie Ltd	Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares
GB201020133D0 (en)	2010-11-26	2011-01-12	Royal Holloway & Bedford New College	Therapeutic use of compounds
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ611606A (en)	2010-11-29	2015-10-30	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
BR112013020346A2 (pt) *	2011-02-11	2019-09-24	Du Pont	concentrado de ácido eicosapentaenoico, produto farmac~eutico, método de elaboração de um concentrado de ácido eicosapentaenoico e uso de óleo microbiano
US8952000B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en)	2011-02-16	2015-09-01	Pivotal Therapeutics, Inc.	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en)	2011-02-16	2014-05-06	Pivotal Therapeutics Inc.	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120252888A1 (en) *	2011-03-29	2012-10-04	Palupa Medical Ltd.	Compositions and Methods for Treating Neurologic Disorders
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
JP6307442B2 (ja)	2012-01-06	2018-04-04	アマリンファーマシューティカルスアイルランドリミテッド	対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
US9452135B2 (en)	2012-03-20	2016-09-27	Particle Dynamics International, Llc	Gelling agent-based dosage form
AU2013284464A1 (en) *	2012-06-29	2015-01-22	Amarin Pharmaceuticals Ireland Limited	Methods of treating pediatric metabolic syndrome
DK3363433T3 (da)	2012-06-29	2021-03-08	Amarin Pharmaceuticals Ie Ltd	Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester
US20150359773A1 (en)	2012-09-26	2015-12-17	Seth D. Feuerstein	Combination methods and compositions including sleep therapeutics for treating mood
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
KR20150103009A (ko) *	2012-12-06	2015-09-09	마티나스 바이오파마, 인코포레이티드	도코사펜타에노산을 포함하는 조성물의 투여
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20150374660A1 (en) *	2013-02-26	2015-12-31	Jiva Pharma, Inc.	Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9428711B2 (en)	2013-05-07	2016-08-30	Groupe Novasep	Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3076978A4 (en) *	2013-12-05	2017-08-16	Enzymotec Ltd.	Serine glycerophospholipid preparation and method for treatment of seizures
EP3118186B1 (fr) *	2013-12-11	2022-02-09	Novasep Process	Installation chromatographique de production d acides gras polyinsatures
BR112016015718B1 (pt)	2014-01-07	2021-12-07	Novasep Process Solutions	Processo de purificação de aminoácidos aromáticos
US9540307B2 (en)	2014-05-08	2017-01-10	Jiva Pharma, Inc.	Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
RU2582962C1 (ru) *	2014-12-23	2016-04-27	Ольга Алексеевна Громова	Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
US10183044B2 (en)	2015-05-15	2019-01-22	P Tech, Llc	Systems and methods for thrombosis prevention
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11065288B2 (en) *	2017-09-29	2021-07-20	Kinjirushi Co., Ltd.	Neuron activator
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190385718A1 (en)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
CN108721269A (zh) *	2018-07-10	2018-11-02	广东海洋大学	一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
MA51765A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3233141A1 (en) *	2020-01-29	2021-08-05	Universitat De Les Illes Balears	Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers
KR20240012390A (ko)	2021-04-21	2024-01-29	애머린 파마슈티칼스 아일랜드 리미티드	심부전의 위험을 감소시키는 방법

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1021147A (en) *	1972-10-30	1977-11-22	Stephen S. Trond	Method for preparing oxysulfide phosphors with large particle size
US4377526A (en)	1981-05-15	1983-03-22	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid and its esters
CA1239587A (en)	1983-10-24	1988-07-26	David Rubin	Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en)	1983-10-24	1985-07-02	Century Laboratories, Inc.	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
US4727340A (en) *	1986-04-30	1988-02-23	Tektronix, Inc.	Comb generators
US4920098A (en) *	1986-09-17	1990-04-24	Baxter International Inc.	Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en)	1987-04-27	1993-10-12	Scotia Holdings Plc	Lithium salt-containing pharmaceutical compositions
DE3719097C1 (de) *	1987-06-06	1988-06-09	Fratzer Uwe	Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
US5198468A (en) *	1987-06-24	1993-03-30	Efamol Holdings Plc	Essential fatty acid composition
US4843095A (en)	1987-08-07	1989-06-27	Century Laboratories, Inc.	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
IE63225B1 (en)	1988-09-13	1995-04-05	Efamol Holdings	Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en)	1988-10-21	1990-04-25	Tillotts Pharma Ag	Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) *	1988-12-19	1990-06-19	Pharmacaps, Inc.	Chewable, edible soft gelatin capsule
JP2839276B2 (ja)	1989-01-23	1998-12-16	日本分光工業株式会社	超臨界流体抽出・分離方法及び装置
US5457130A (en)	1989-03-20	1995-10-10	Cancer Research Campaign Technology Limited	Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) *	1989-03-20	1989-05-04	Tisdale Michael J	Eicosapentaenoic acid
JPH0358926A (ja) *	1989-07-27	1991-03-14	Taiyo Fishery Co Ltd	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
CA2043615C (en) *	1990-06-04	2001-08-14	Kazuhiko Hata	Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en)	1990-06-06	1990-07-25	Efamol Holdings	Essential fatty acid treatment
JP3103588B2 (ja) *	1990-11-16	2000-10-30	持田製薬株式会社	リポプロテイン（ａ）低下剤
SE9101642D0 (sv)	1991-05-30	1991-05-30	Kabi Pharmacia Ab	Phospholipids
US5215630A (en)	1991-06-04	1993-06-01	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
DE4133694C2 (de) *	1991-10-11	1993-10-07	Fresenius Ag	Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) *	1991-10-28	2003-04-28	日本水産株式会社	高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) *	1992-07-28	1994-02-22	Maruha Corp	ω−３不飽和脂肪酸系化合物の安定化法
US5516801A (en) *	1992-08-21	1996-05-14	Scotia Holdings Plc	Fatty acid treatment for ectopic calcium deposition
US5888541A (en)	1992-08-21	1999-03-30	Scotia Holdings Plc	Fatty acid treatment
GB9217780D0 (en)	1992-08-21	1992-10-07	Efamol Holdings	Fatty acid treatment
GB9300125D0 (en) *	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
AU7053494A (en)	1993-06-04	1995-01-03	Martek Biosciences Corporation	Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en)	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
US5760081A (en)	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en)	1994-06-28	1999-10-14	Scotia Holdings Plc	Compositions for treatment of diabetic complications
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) *	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) *	1995-05-15	1995-07-05	Tillotts Pharma Ag	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
GB9519661D0 (en) *	1995-09-27	1995-11-29	Scotia Holdings Plc	Fatty acid treatment
JP3552810B2 (ja)	1995-09-27	2004-08-11	松下電器産業株式会社	部品供給部の部品一括交換方法と装置
WO1997039759A2 (en) *	1996-04-24	1997-10-30	Brigham And Women's Hospital	Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) *	1996-10-02	2002-05-09	Bockow Barry I.	Compositions and methods for treating cardiovascular conditions
TR199900786T2 (xx) *	1996-10-11	1999-07-21	Scotia Holdings Plc	Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
CA2307776C (en)	1997-10-30	2008-01-15	Morishita Jintan Co., Ltd.	Capsular preparation containing unsaturated fatty acid or derivative thereof and process for producing the same
KR100587551B1 (ko) *	1997-12-10	2006-06-08	싸이클로스포린 테라퓨틱스 리미티드	오메가-3 지방산 오일을 함유하는 약학 조성물
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) *	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) *	1999-03-01	2001-02-27	Banner Pharmacaps, Inc.	Gum acacia substituted soft gelatin capsules
PT1072198E (pt) *	1999-07-28	2008-06-17	Swiss Caps Rechte & Lizenzen	Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
EP1211955A1 (en)	1999-08-30	2002-06-12	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
DE60022987T2 (de)	2000-05-22	2006-10-19	Pro Aparts - Investimentos E Consultoria Lda., Funchal	Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
ITMI20010129A1 (it)	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en)	2001-05-09	2001-06-27	Laxdale Ltd	Potentiation of therapeutic effects of fatty acids
EP1390025B1 (en)	2001-05-30	2005-03-30	Laxdale Limited	Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
ITMI20012384A1 (it)	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it)	2002-02-12	2003-08-12	Victorix Assets Ltd	Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
US20030166614A1 (en) *	2002-03-01	2003-09-04	Harrison Stanley F.	Method for reducing cholesterol and triglycerides
US7314643B2 (en) *	2002-08-20	2008-01-01	Nikken Chemicals Co., Ltd.	Soft capsule preparation
US20070087137A9 (en) *	2003-06-26	2007-04-19	Elwakil Hamdy A	Decorative laminated safety glass
KR100539027B1 (ko)	2002-10-18	2005-12-26	현대모비스 주식회사	차량의 조향각 검출 장치
AU2003284617A1 (en) *	2002-11-22	2004-06-18	Nippon Suisan Kaisha, Ltd.	Composition containing organic substance having double bond with improved oxidation stability
MXPA05009432A (es)	2003-03-05	2005-11-23	Solvay Pharm Gmbh	Uso de acidos grasos omega-3 en el tratamiento de pacientes diabeticos.
GB2409644B (en) *	2003-12-31	2005-12-21	Igennus Ltd	Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
JP2008522970A (ja) *	2004-12-06	2008-07-03	レリアントファーマスーティカルズインコーポレイテッド	脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤
US20070191467A1 (en) *	2004-12-06	2007-08-16	Reliant Pharmaceutical, Inc.	Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) *	2004-12-22	2006-06-22	Bortz Jonathan D	Cardiovascular compositions
GB2421909A (en)	2004-12-23	2006-07-12	Laxdale Ltd	Pharmaceutical compositions comprising EPA and methods of use
US7628027B2 (en)	2005-07-19	2009-12-08	Hussmann Corporation	Refrigeration system with mechanical subcooling
ITMI20051560A1 (it)	2005-08-10	2007-02-11	Tiberio Bruzzese	Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070104779A1 (en) *	2005-11-07	2007-05-10	Rongen Roelof M	Treatment with omega-3 fatty acids and products thereof
MX286464B (es) *	2005-12-20	2011-05-10	Cenestra Llc	Formulaciones de acido graso omega 3.
CA2802892A1 (en) *	2006-02-07	2007-08-07	Mochida Pharmaceutical Co. Ltd.	Composition for preventing recurrence of stroke
US20090304784A1 (en) *	2006-07-28	2009-12-10	V. Mane Fils	Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EP3865128A1 (en) *	2009-02-10	2021-08-18	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
KR20120016677A (ko) *	2009-06-15	2012-02-24	아마린 파마, 인크.	병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
EP2861227A4 (en) *	2012-06-17	2016-01-27	Matinas Biopharma Inc	OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE

1999
- 1999-01-27 GB GBGB9901809.5A patent/GB9901809D0/en not_active Ceased
2000
- 2000-01-21 CZ CZ20012695A patent/CZ20012695A3/cs unknown
- 2000-01-21 EE EEP200100387A patent/EE04629B1/xx not_active IP Right Cessation
- 2000-01-21 CA CA002360776A patent/CA2360776C/en not_active Expired - Fee Related
- 2000-01-21 EP EP00900733A patent/EP1148873B1/en not_active Expired - Lifetime
- 2000-01-21 MX MXPA01007662A patent/MXPA01007662A/es not_active IP Right Cessation
- 2000-01-21 ES ES00900733T patent/ES2246825T3/es not_active Expired - Lifetime
- 2000-01-21 EP EP03079169A patent/EP1417963A1/en not_active Ceased
- 2000-01-21 DK DK00900733T patent/DK1148873T3/da active
- 2000-01-21 HU HU0105215A patent/HU226713B1/hu not_active IP Right Cessation
- 2000-01-21 AT AT00900733T patent/ATE300296T1/de active
- 2000-01-21 PL PL349718A patent/PL199778B1/pl not_active IP Right Cessation
- 2000-01-21 CN CNA2005101097522A patent/CN1739496A/zh active Pending
- 2000-01-21 WO PCT/GB2000/000164 patent/WO2000044361A2/en not_active Application Discontinuation
- 2000-01-21 NZ NZ513172A patent/NZ513172A/en not_active IP Right Cessation
- 2000-01-21 AU AU30657/00A patent/AU3065700A/en not_active Abandoned
- 2000-01-21 IL IL14450200A patent/IL144502A0/xx active IP Right Grant
- 2000-01-21 TR TR2005/04156T patent/TR200504156T2/xx unknown
- 2000-01-21 JP JP2000595665A patent/JP4959055B2/ja not_active Expired - Fee Related
- 2000-01-21 KR KR1020017009388A patent/KR100760038B1/ko not_active IP Right Cessation
- 2000-01-21 PT PT00900733T patent/PT1148873E/pt unknown
- 2000-01-21 RU RU2001121185/14A patent/RU2260423C2/ru not_active IP Right Cessation
- 2000-01-21 RS YUP-542/01A patent/RS50133B/sr unknown
- 2000-01-21 DE DE60021525T patent/DE60021525T2/de not_active Expired - Lifetime
- 2000-01-21 SK SK1039-2001A patent/SK10392001A3/sk unknown
- 2000-01-21 CN CNB008032025A patent/CN100423718C/zh not_active Expired - Fee Related
- 2000-01-21 UA UA2001085934A patent/UA76405C2/uk unknown
- 2000-01-21 BR BR0007743-7A patent/BR0007743A/pt active Pending
- 2000-01-21 TR TR2001/02170T patent/TR200102170T2/xx unknown
- 2000-01-26 MY MYPI20000272A patent/MY136927A/en unknown
- 2000-01-27 US US09/492,741 patent/US6384077B1/en not_active Expired - Lifetime
- 2000-03-07 TW TW089101385A patent/TWI228041B/zh active
2001
- 2001-06-29 IS IS5988A patent/IS5988A/is unknown
- 2001-07-17 NO NO20013546A patent/NO20013546L/no not_active Application Discontinuation
- 2001-07-23 IL IL144502A patent/IL144502A/en not_active IP Right Cessation
- 2001-07-25 ZA ZA200106105A patent/ZA200106105B/xx unknown
- 2001-07-25 HR HR20010558A patent/HRP20010558A2/hr not_active Application Discontinuation
- 2001-12-14 US US10/014,603 patent/US6689812B2/en not_active Expired - Lifetime
2002
- 2002-01-29 HK HK02100688.5A patent/HK1039564B/zh not_active IP Right Cessation
- 2002-06-19 US US10/173,622 patent/US20020183389A1/en not_active Abandoned
- 2002-07-10 US US10/191,430 patent/US7119118B2/en not_active Expired - Fee Related
2004
- 2004-02-12 US US10/776,226 patent/US20040162348A1/en not_active Abandoned
2006
- 2006-02-24 US US11/361,069 patent/US20060252833A1/en not_active Abandoned
2008
- 2008-03-20 US US12/052,598 patent/US8188146B2/en not_active Expired - Fee Related
2010
- 2010-11-22 US US12/951,620 patent/US20110065793A1/en not_active Abandoned
2012
- 2012-04-04 US US13/439,392 patent/US20120195963A1/en not_active Abandoned
2013
- 2013-09-16 US US14/028,451 patent/US20140073692A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0105215A2 (hu)	2002-05-29
US20040162348A1 (en)	2004-08-19
TWI228041B (en)	2005-02-21
US20110065793A1 (en)	2011-03-17
US20120195963A1 (en)	2012-08-02
RU2260423C2 (ru)	2005-09-20
PT1148873E (pt)	2005-11-30
EP1148873B1 (en)	2005-07-27
AU3065700A (en)	2000-08-18
ES2246825T3 (es)	2006-03-01
CZ20012695A3 (cs)	2002-02-13
DE60021525T2 (de)	2006-06-01
HK1039564B (zh)	2005-12-09
JP2002535355A (ja)	2002-10-22
EE04629B1 (et)	2006-06-15
CA2360776A1 (en)	2000-08-03
DK1148873T3 (da)	2005-11-28
HU226713B1 (en)	2009-07-28
NO20013546D0 (no)	2001-07-17
UA76405C2 (en)	2006-08-15
HRP20010558A2 (en)	2002-08-31
TR200102170T2 (tr)	2001-12-21
US20020193439A1 (en)	2002-12-19
HUP0105215A3 (en)	2002-09-30
PL199778B1 (pl)	2008-10-31
GB9901809D0 (en)	1999-03-17
NZ513172A (en)	2003-10-31
CA2360776C (en)	2009-07-14
HK1039564A1 (en)	2002-05-03
NO20013546L (no)	2001-09-25
US20020077361A1 (en)	2002-06-20
CN1739496A (zh)	2006-03-01
DE60021525D1 (de)	2005-09-01
JP4959055B2 (ja)	2012-06-20
KR20010108131A (ko)	2001-12-07
WO2000044361A3 (en)	2000-12-21
IS5988A (is)	2001-06-29
TR200504156T2 (tr)	2006-07-21
EP1417963A1 (en)	2004-05-12
CN1338929A (zh)	2002-03-06
ATE300296T1 (de)	2005-08-15
US20140073692A1 (en)	2014-03-13
IL144502A0 (en)	2002-05-23
US6689812B2 (en)	2004-02-10
IL144502A (en)	2006-12-31
EP1148873A2 (en)	2001-10-31
ZA200106105B (en)	2003-04-30
MY136927A (en)	2008-11-28
CN100423718C (zh)	2008-10-08
YU54201A (sh)	2004-07-15
RS50133B (sr)	2009-03-25
EE200100387A (et)	2003-02-17
KR100760038B1 (ko)	2007-10-04
US8188146B2 (en)	2012-05-29
BR0007743A (pt)	2001-11-27
US20020183389A1 (en)	2002-12-05
WO2000044361A2 (en)	2000-08-03
US20080200547A1 (en)	2008-08-21
MXPA01007662A (es)	2003-06-24
US6384077B1 (en)	2002-05-07
US20060252833A1 (en)	2006-11-09
US7119118B2 (en)	2006-10-10

Legal Events

Date	Code	Title	Description
2010-10-07	FD9A	Suspended procedure due to non-payment of fee

Publication	Publication Date	Title
SK10392001A3 (sk)	2002-02-05	Farmaceutické prostriedky na liečbu alebo prevenciu psychiatrických ochorení alebo porúch centrálneho nervového systému obsahujúce EPA
JP5087280B2 (ja)	2012-12-05	中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用
SK13652003A3 (sk)	2004-07-07	Potenciácia terapeutického účinku mastných kyselín
Bowden	2001	Novel treatments for bipolar disorder
JPWO2007064010A1 (ja)	2009-05-07	アルツハイマー型認知症予防・治療剤
AU2006201772B2 (en)	2010-02-04	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
AU2004235641B2 (en)	2006-09-14	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US20070082949A1 (en)	2007-04-12	Agent for preventing and treating language disorders